Skip to main content
Ipsen logo

Ipsen — Investor Relations & Filings

Ticker · IPN ISIN · FR0010259150 LEI · 549300M6SGDPB4Z94P11 PA Manufacturing
Open in API
Filings indexed 1,378 across all filing types
Latest filing 2024-09-15 Legal Proceedings Report
Country FR France
Listing PA IPN

About Ipsen

https://www.ipsen.com/

Ipsen is a global biopharmaceutical company focused on innovation and specialty care. The company develops and commercializes transformative medicines to address high unmet medical needs in three key therapeutic areas: oncology, rare diseases, and neuroscience. By leveraging its specialized expertise and strategic partnerships, Ipsen aims to accelerate the development of new therapies and improve health outcomes for patients worldwide. Its strategy is centered on advancing science with purpose to bring innovative treatments from research and development to the market.

Recent filings

Filing Released Lang Actions
Ipsen provides update on CONTACT-02 Phase III trial in metastatic castration-resistant prostate cancer following final overall survival analysis
Legal Proceedings Report Classification · 1% confidence The document is a press release from Ipsen dated September 15, 2024, providing an update on the Phase III CONTACT-02 trial results for Cabometyx in metastatic castration-resistant prostate cancer (mCRPC). It details the outcome of the final overall survival analysis, states that Ipsen will not pursue regulatory submissions for the combination regimen in certain regions, and includes extensive background information on the drug, the disease, and the trial itself. This content structure—a formal announcement of clinical trial results, strategic decisions based on those results, and forward-looking statements—is characteristic of an Earnings Release (ER) or a general corporate/investor update. Since it is a specific announcement of clinical data and strategic implications rather than a full quarterly financial report (10-Q/10-K) or a transcript of a call, the most appropriate classification is Earnings Release (ER), as these often include key operational and clinical milestones alongside financial highlights, or sometimes serve as the primary vehicle for such news if not tied to a formal earnings report period. Given the focus on trial results and strategic decisions, ER is a strong fit, although it could also be considered a Regulatory Filing (RNS) if it were purely a disclosure. However, the detailed nature suggests a primary communication to investors, aligning best with ER.
2024-09-15 English
Ipsen communique de nouvelles données sur l’essai de Phase III CONTACT-02 dans le cancer de la prostate métastatique résistant à la castration au terme de l’analyse finale de la survie globale
Regulatory Filings Classification · 1% confidence The document is titled "Communiqué de presse" (Press Release) and announces clinical trial results (Phase III CONTACT-02) for a drug (Cabometyx®) in prostate cancer. It details the statistical outcomes (survival rates, hazard ratios) and the subsequent business decision not to pursue regulatory submissions in certain territories. This content is characteristic of an initial announcement of periodic financial/clinical performance highlights, rather than the full, comprehensive report (like a 10-K or IR). It is a formal announcement intended for immediate public dissemination to investors and media regarding key operational/clinical milestones. This aligns best with the 'Earnings Release' (ER) category, which serves as the primary vehicle for announcing key periodic results, even if the results here are clinical rather than purely financial earnings figures. Given the context of a pharmaceutical company, clinical trial updates often fall under the broader umbrella of periodic performance announcements.
2024-09-15 French
Ipsen - Août 2024 - Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document is titled "Information mensuelle relative au nombre total des droits de vote et d'actions composant le capital social" (Monthly information relating to the total number of voting rights and shares comprising the share capital). It explicitly references French regulatory articles (Code de commerce and AMF General Regulation) and provides a table detailing the total number of shares and voting rights as of August 31, 2024. This content directly relates to changes in the capital structure and voting rights, which aligns best with the 'Share Issue/Capital Change' category (SHA) or potentially a general regulatory filing (RNS). However, since it specifically details the composition of the capital and voting rights, SHA is the most precise fit among the defined categories, as it concerns the capital structure.
2024-09-04 French
Ipsen - August 2024 - Monthly information relative to the total number of voting rights and shares composing the share capital
Declaration of Voting Results & Voting Rights Announcements Classification · 1% confidence The document explicitly states it provides 'Monthly information relative to the total number of voting rights and shares composing the share capital' as required by French Commercial Code and AMF regulations. This content details the total share count and the total number of voting rights (gross and net) as of a specific date (August 31, 2024). This type of periodic disclosure regarding the capital structure and voting power is most closely aligned with notifications concerning share capital changes or major shareholdings, but given the specific focus on voting rights calculation, it fits best under the general category of capital structure updates or regulatory disclosures. Since there is no specific code for 'Monthly Voting Rights Disclosure', I must choose the closest fit. It is not a standard 10-K, IR, or ER. It is a periodic update on the share base. The closest specific category that deals with share counts and ownership thresholds is 'Major Shareholding Notification' (MRQ), although this is a general monthly update rather than a specific threshold crossing. However, given the options, this document is a mandatory regulatory disclosure concerning the composition of the share capital and voting rights, which is a fundamental aspect of shareholder structure reporting. Since it is a specific, recurring regulatory disclosure that doesn't fit the other specific categories (like DIV, CAP, or DIRS), it falls under the general regulatory filing category, RNS, or potentially MRQ if interpreted as a periodic update related to share ownership structure. Given the precise nature of the data (total shares and voting rights), it is a specific regulatory filing. I will classify it as RNS (Regulatory Filings) as it is a mandatory, periodic regulatory disclosure that doesn't match the other specific codes like DIV, CAP, or MRQ (which usually reports a *crossing* of a threshold, not the monthly total).
2024-09-04 English
IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 32 - 2024
Transaction in Own Shares Classification · 1% confidence The document text consists of tables detailing transactions involving the issuer (IPSEN) and a third party (Natixis) regarding the purchase or sale of the issuer's own shares. Key indicators are the columns 'Volume total journalier (en nombre de titres)' and 'Objectif du rachat' which mentions 'MAR Regulation Art 5 §2'. This structure strongly suggests a report detailing transactions in the company's own shares, which aligns with the definition of 'Transaction in Own Shares' (POS). The data is granular transaction data, not a general announcement of a report (RPA/RNS).
2024-08-13 French
IPSEN - Buy-back programme - Art 5 of MAR - Week 32 - 2024
Transaction in Own Shares Classification · 1% confidence The document text consists of detailed tables reporting transactions involving the issuer's shares ('Name of the Issuer', 'Total daily volume', 'Price per unit', 'Purpose of the buyback'). Specifically, the second table includes a column titled 'Purpose of the buyback' with entries like 'MAR Regulation Art 5 §2', which strongly indicates a report detailing transactions in the company's own shares, often related to buyback programs. This aligns perfectly with the definition for 'Transaction in Own Shares' (POS).
2024-08-13 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.